



BIOSIMILAR MEDICINES: A SUSTAINABLE SOLUTION FOR COMPLEX CONDITIONS

A **biologic medicine** contains a **biological active substance**. A **biosimilar medicine** contains a version of a biological active substance already authorised in a reference medicine, **improving patients' choice** thanks to increased competition.

BIOSIMILAR MEDICINES TREAT CHRONIC AND ACUTE CONDITIONS



245 biologic medicines approved in Europe ¹




More than 35 years of experience with biologic medicines

Biosimilar medicines are already available to millions of patients for **key therapeutic areas** every day.



Cancer



Rheumatoid arthritis



Psoriasis



Crohn's disease



Growth disorder




Diabetes




EU approved biosimilar medicines have delivered **700 million** patient days of treatment since 2006 ²

BIOSIMILAR MEDICINES: EQUIVALENT TREATMENT OPTIONS



EU approved biosimilar medicines match the **same safety, efficacy and high quality** as their reference medicine

BIOSIMILAR MEDICINES: A COST-EFFECTIVE CHOICE



The introduction of biosimilar medicines **enables more patients to access treatment** (up to 100% more)



Biosimilar medicines: budget friendly equivalent treatment



Potential gain for European healthcare systems over the next 5 years - **greater than 15 billion Euro** ³



Reinvestments in needed healthcare products and services ⁴

BIOSIMILAR MEDICINES: HOW CAN WE REALISE THEIR POTENTIAL?



Awareness and education by health authorities



Multistakeholder benefit sharing schemes (patients, payers, governments, healthcare professionals) ⁵



Ensure sustainability of biosimilar medicines market

REFERENCES

- 1 / Biopharmaceutical benchmarks 2014, G. Walsh, Volume 32, Number 10, October 2014, Nature Biotechnology
- 2 / Medicines for Europe information based on EMA Post-authorisation Safety Update Reports (PSURs)
- 3 / Delivering on the Potential of Biosimilar Medicines - The Role of Functioning Competitive Markets; Published in March 2016; Available from: https://www.imshealth.com/files/web/IMSH%20Institute/Healthcare%20Briefs/Documents/IMS_Institute_Biosimilar_Brief_March_2016.pdf
- 4 / GfK EGA Sustainability Study 2014 September 9, Pg. 36
- 5 / Payers' price & market access policies supporting a sustainable biosimilar medicines market, Simon Kucher & Partners; Published in September 2016; Available from: http://www.medicinesforeurope.com/wp-content/uploads/2016/09/Simon-Kucher-2016-Policy-requirements-for-a-sustainable-biosimilar-market-FINAL-report_for-publication.pdf